We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
SER | Strategic Energy Resources Limited | 0.033 | 0.017 | 106.25% | 103,636,351 | 1,072 |
RR1OA | Reach Resources Ltd | 0.007 | 0.003 | 75.00% | 84,054 | 3 |
KED | Keypath Education International Inc | 0.83 | 0.295 | 55.14% | 499,536 | 92 |
REEO | RareX Limited | 0.003 | 0.001 | 50.00% | 1,158,605 | 3 |
CPOO | Culpeo Minerals Ltd | 0.006 | 0.002 | 50.00% | 526,390 | 1 |
AN1 | Anagenics Ltd | 0.01 | 0.003 | 42.86% | 5,481,308 | 57 |
T3D | 333D Limited | 0.008 | 0.002 | 33.33% | 487,613 | 3 |
GMN | Gold Mountain Limited | 0.004 | 0.001 | 33.33% | 7,853,019 | 16 |
EDE | Eden Innovations Ltd | 0.002 | 0.0005 | 33.33% | 1,914,026 | 4 |
NAE | New Age Exploration Limited | 0.004 | 0.001 | 33.33% | 885,170 | 6 |
FTZ | Fertoz Limited | 0.04 | 0.01 | 33.33% | 33,338 | 3 |
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)’s Medical Devices Advisory Committee has strongly recommended FDA approval of the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
NEW YORK, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- On May 17, 2024, SCWorx Corp. (the “Company”) received a further notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q for the period ended March 31, 2024, and because it remains delinquent in filing its Form 10-K for the year ended December 31, 2023, the Company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC. ...
BEIJING, May 24, 2024 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced it will host a conference call to discuss first quarter 2024 results on Thursday, May 30, 2024, at 8:00 a.m. EST.
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD shareholders participating in the offerings. The closings of the two private placements are each subject to customary closing conditions and are both expected to occur on or ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,350.62 | -573.96 | -0.84% | 1.32T | 5,704,663,302 |
ETH | Ethereum | 3,705.63 | -69.89 | -1.85% | 445.86B | 9,184,313,401 |
GALA | Gala | 3.57 | 3.53 | 8,110.67% | 120.7B | 75,415,273 |
USDT | Tether USD | 0.99951 | 0.00005 | 0.01% | 97.79B | 318,670,093 |
BNB | Binance Coin | 597.42 | -1.34 | -0.22% | 94.27B | 420,150,562 |
SOL | Solana | 166.11 | -9.89 | -5.62% | 73.45B | 1,922,698,915 |
STETH | stETH | 3,703.52 | -70.87 | -1.88% | 36.38B | 54,429,808 |
XRP | Ripple | 0.5304 | 0.0019 | 0.36% | 28.98B | 567,659,188 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 1,604,034,710 |
DOGE | Dogecoin | 0.16355 | 0.00392 | 2.46% | 23.39B | 1,008,715,881 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions